Harmony Biosciences (HRMY) Stock Price, News & Analysis

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 2 sell ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HRMY shares.
View HRMY analyst ratings or view top-rated stocks.

8 equities research analysts have issued 12 month target prices for Harmony Biosciences' shares. Their HRMY share price targets range from $27.00 to $59.00. On average, they anticipate the company's stock price to reach $40.63 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price.
View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts.

Harmony Biosciences' stock was trading at $32.30 at the beginning of 2024. Since then, HRMY shares have decreased by 10.1% and is now trading at $29.03.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our HRMY earnings forecast.

Harmony Biosciences will be holding an earnings conference call on Tuesday, April 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) issued its earnings results on Thursday, February, 22nd. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.74 by $0.29. The company earned $168.40 million during the quarter, compared to analyst estimates of $168.90 million. Harmony Biosciences had a net margin of 22.16% and a trailing twelve-month return on equity of 27.49%. The firm's revenue was up 31.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.01 EPS.

ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Products ETF (BBP), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows 100 ETF (CALF) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Harmony Biosciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $712.3 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Harmony Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.06%), Los Angeles Capital Management LLC (0.04%) and Hennion & Walsh Asset Management Inc. (0.03%). Insiders that own company stock include Andreas Wicki, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs.
View institutional ownership trends.

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.